Nevada APRN Bundle

Course Overview

Course Authors

1. Sarah Schulze MSN, NP
2. Morgan Curry BSN, RN
3. Tracey Long PHD, APRN-BC, CCRN, CDCES, CNE, COI
4. Abbie Schmitt MSN, RN
5. Madeira Fountaine MSN, RN, PHN
6. Amy White, CNO, RN
7. Maureen Sullivan-Tevault MS, BSN, RN, CEN, CDE
8. Amanda Marten MSN, FNP-C
9. Edith Fomuso MSN, CCM, RN
10. Sadia A. MPH, MSN, WHNP-BC
11. Cathleen Adams CNO, RN CENP
12. Charmaine Robinson MSN-Ed, BSN, RN
13. R.E. Hengsterman MSN, RN, MA
14. Karson Carter RN,BSN, CPN

Course Outline

1. Nevada Cultural Competence in Nursing (DEI Requirement)
2. Bioterrorism in Nursing
3. Suicide Risk ER Admission
4. Nevada HIV: Stigma, Discrimination.
5. End of Life Process
6. Tirzepatide for Type 2 Diabetes and Weight Management
7. Semaglutide and Type 2 Diabetes
8. Medication Assisted Treatment
9. Hypertensive Agents
10. Migraine Management
11. Asthma Treatment and Monitoring
12. SSRI Use in Major Depressive Disorder
13. Antibiotic Use in UTI
14. Oral STI Medications
15. Controlled Substances: A comprehensive review
16. Anticoagulant Therapy
17. SNRIs for Depression
18. Corticosteroid Therapy
19. Anti-arrhythmics
20. Nursing Care in Lewy Body Dementia

Accreditation Statement

Nursing CE Central LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In this course, we will discuss APRN courses pertinent to renewal in Nevada. It will take the average learner 2700 minutes to complete and awards contact hours of continuing education.

Course Outcomes

After completing this course, the learner will rate a 4 out of 5 on the Likert Scale for their ability to:

1. Identify ways that people of minority groups experience healthcare differently than other patients.
2. Understand how syndromic surveillance is used in identifying potential acts of bioterrorism, the reporting procedures and the use of the Health Alert Network.
3. Define terms of suicide, suicide attempt, and suicidal ideation.
4. Understand the legal protections against discrimination for patients who are HIV-positive in Nevada and the United States.
5. Identify the phases of dying.
6. Understand the drug classification of tirzepatide
7. Describe the action of non-insulin injectable diabetes medication semaglutide.
8. Discuss the prevalence of various substance-related problems among United States citizens.  
9. Differentiate between the classes of antihypertensives and their mechanism of action. 
10. Demonstrate understanding of the neurobiological and pathophysiological mechanisms underlying migraines.  
11. Describe common side effects, including severe possible side effects, of medications used to manage asthma
12. Describe common side effects, including severe possible side effects, of SSRIs
13. Differentiate between uncomplicated and complicated UTI and summarize key considerations when prescribing antibiotics for UTI.
14. Discuss the clinical criteria for prescribing oral STI medications.
15. Describe commonly prescribed opioids for pain management and understand their side effects and indications of use.
16. Identify potential anticoagulants and differentiate between the classes of anticoagulants and their mechanism of action.
17. Identify the types and uses of Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs).
18. Describe the effect that corticosteroids have on the immune system.
19. Discuss the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs, including drug absorption, distribution, metabolism, and excretion.
20. Summarize how family support plays a role in the management of Lewy Body dementia.

Target Audience

• Registered Nurses (RN)
• Advanced Practice Registered Nurses (APRN)

Requirement for Completion

1. Enrollment in the course by the learner
2. Read and learn all course materials
3. Complete the course evaluation
4. Attest and testify learning of the course materials

Accreditations + Approvals

Disclosure of Relevant Financial Relationships

Nursing CE Central nor any of the authors, planners, content experts, or any contributors have any relevant financial relationships with ineligible companies to disclose.